What You Should Know
For Health Professionals
For the Media
Pneumococcal conjugate vaccine (PCV13) is recommended for all children younger than 5 years old, all adults 65 years or older, and people 6 years or older with certain risk factors. Pneumococcal polysaccharide vaccine (PPSV23) is recommended for all adults 65 years or older. People 2 through 64 years old who are at high risk of pneumococcal disease should also receive PPSV23.
The pneumococcal conjugate vaccine, PCV13 or Prevnar 13®, is currently recommended for all children younger than 5 years old, all adults 65 years or older, and people 6 through 64 years old with certain medical conditions.
Pneumovax® is a 23-valent pneumococcal polysaccharide vaccine (PPSV23) that is currently recommended for use in all adults 65 years or older and for people who are 2 years or older and at high risk for pneumococcal disease (e.g., those with sickle cell disease, HIV infection, or other immunocompromising conditions). PPSV23 is also recommended for use in adults 19 through 64 years old who smoke cigarettes or who have asthma.
As with all vaccines, there can be minor reactions, including pain and redness at the injection site, headache, fatigue or a vague feeling of discomfort.
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more